{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T21:17:54Z","timestamp":1788297474285,"version":"build-2803163510"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["787270"],"award-info":[{"award-number":["787270"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.bone.2020.115465","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T05:06:06Z","timestamp":1591333566000},"page":"115465","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Bisphosphonates in the management of Paget's disease"],"prefix":"10.1016","volume":"138","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2804-7586","authenticated-orcid":false,"given":"Stuart H.","family":"Ralston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bone.2020.115465_bb0005","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00223-019-00522-3","article-title":"Paget\u2019s disease of bone","volume":"104","author":"Gennari","year":"2019","journal-title":"Calcif. Tissue Int."},{"issue":"10","key":"10.1016\/j.bone.2020.115465_bb0010","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/art.1780231005","article-title":"Bone histomorphometry in Paget\u2019s disease. Quantitative and dynamic analysis of pagetic and nonpagetic bone tissue","volume":"23","author":"Meunier","year":"1980","journal-title":"Arthritis Rheum."},{"issue":"1\u20132","key":"10.1016\/j.bone.2020.115465_bb0015","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/0378-5955(94)00196-W","article-title":"Hearing loss in Paget\u2019s disease of bone: the relationship between pure-tone thresholds and mineral density of the cochlear capsule","volume":"83","author":"Monsell","year":"1995","journal-title":"Hear. Res."},{"issue":"3","key":"10.1016\/j.bone.2020.115465_bb0020","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1359\/jbmr.2002.17.3.465","article-title":"Incidence and natural history of Paget\u2019s disease of bone in England and Wales","volume":"17","author":"van Staa","year":"2002","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2020.115465_bb0025","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00223-014-9904-1","article-title":"Clinical presentation of Paget\u2019s disease: evaluation of a contemporary cohort and systematic review","volume":"95","author":"Tan","year":"2014","journal-title":"Calcif. Tissue Int."},{"issue":"7","key":"10.1016\/j.bone.2020.115465_bb0030","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/cncr.24121","article-title":"Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program","volume":"115","author":"Mirabello","year":"2009","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.bone.2020.115465_bb0035","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.bone.2013.04.024","article-title":"Epidemiology of Paget\u2019s disease of bone: a systematic review and meta-analysis of secular changes","volume":"55","author":"Corral-Gudino","year":"2013","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bone.2020.115465_bb0040","first-page":"94","article-title":"Paget\u2019s disease (Osteitis deformans) and heredity","volume":"1","author":"Montagu","year":"1949","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bone.2020.115465_bb0045","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/jbmr.5650060511","article-title":"Familial aggregation of Paget\u2019s disease of bone","volume":"6","author":"Siris","year":"1991","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115465_bb0050","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/jech.37.3.226","article-title":"A family study of Paget\u2019s disease of bone","volume":"37","author":"Sofaer","year":"1983","journal-title":"J. Epidemiol. Community Health"},{"issue":"7","key":"10.1016\/j.bone.2020.115465_bb0055","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/ng.845","article-title":"Genome-wide association identifies three new susceptibility loci for Paget\u2019s disease of bone","volume":"43","author":"Albagha","year":"2011","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bone.2020.115465_bb0060","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/ng.562","article-title":"Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget\u2019s disease of bone","volume":"42","author":"Albagha","year":"2010","journal-title":"Nat. Genet."},{"issue":"5","key":"10.1016\/j.bone.2020.115465_bb0065","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00223-019-00520-5","article-title":"Rare inherited forms of Paget\u2019s disease and related syndromes","volume":"104","author":"Ralston","year":"2019","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2020.115465_bb0070","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.3964","article-title":"The loss of profilin 1 causes early onset Paget\u2019s disease of bone","author":"Scotto di Carlo","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115465_bb0075","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1002\/jbmr.1975","article-title":"Common susceptibility alleles and SQSTM1 mutations predict disease extent and severity in a multinational study of patients with Paget\u2019s disease","volume":"28","author":"Albagha","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115465_bb0080","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.4090","article-title":"A new gene for susceptibility to Paget\u2019s disease of bone and for multisystem proteinopathy","author":"Ralston","year":"2020","journal-title":"J. Bone Miner. Res."},{"issue":"8","key":"10.1016\/j.bone.2020.115465_bb0085","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1212\/WNL.0000000000001862","article-title":"Multisystem proteinopathy: intersecting genetics in muscle, bone, and brain degeneration","volume":"85","author":"Taylor","year":"2015","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.bone.2020.115465_bb0090","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.bone.2013.04.024","article-title":"Epidemiology of Paget\u2019s disease of bone: a systematic review and meta-analysis of secular changes","volume":"55","author":"Corral-Gudino","year":"2013","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.bone.2020.115465_bb0095","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S8756-3282(02)00833-5","article-title":"Paget's disease of bone in Lancashire and arsenic pesticide in cotton mill wastewater: a speculative hypothesis","volume":"31","author":"Lever","year":"2002","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.bone.2020.115465_bb0100","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/0049-0172(94)90037-X","article-title":"Epidemiological aspects of Paget's disease: family history and relationship to other medical conditions","volume":"23","author":"Siris","year":"1994","journal-title":"Semin Arth Rheum"},{"key":"10.1016\/j.bone.2020.115465_bb0105","first-page":"226","article-title":"Distribution of Paget\u2019s diease in England, Wales and Scotland and a possible relationship with vitamin D deficiency in childhood","volume":"28","author":"Barker","year":"1974","journal-title":"Br. J. Prev. Soc. Med."},{"issue":"6168","key":"10.1016\/j.bone.2020.115465_bb0110","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1136\/bmj.1.6168.931","article-title":"Billiard-player\u2019s fingers: an unusual case of Paget\u2019s disease of bone","volume":"1","author":"Solomon","year":"1979","journal-title":"Br. Med. J."},{"issue":"12","key":"10.1016\/j.bone.2020.115465_bb0115","first-page":"767","article-title":"Ultrastructural characteristics of osteoclasts in Paget's disease","volume":"41","author":"Rebel","year":"1974","journal-title":"Rev. Rhum. Mal Osteoartic"},{"key":"10.1016\/j.bone.2020.115465_bb0120","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(85)90852-9","article-title":"Past pets and Paget's disease","volume":"2","author":"O'Driscoll","year":"1985","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bone.2020.115465_bb0125","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1006\/viro.1993.1580","article-title":"Mice transgenic for HTLV-I LTR-tax exhibit tax expression in bone, skeletal alterations, and high bone turnover","volume":"197","author":"Ruddle","year":"1993","journal-title":"Virology"},{"issue":"3","key":"10.1016\/j.bone.2020.115465_bb0130","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1359\/JBMR.051108","article-title":"Expression of measles virus nucleocapsid protein in osteoclasts induces Paget\u2019s disease-like bone lesions in mice","volume":"21","author":"Kurihara","year":"2006","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2020.115465_bb0135","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.cmet.2010.12.002","article-title":"Contributions of the measles virus nucleocapsid gene and the SQSTM1\/p62(P392L) mutation to Paget\u2019s disease","volume":"13","author":"Kurihara","year":"2011","journal-title":"Cell Metab."},{"issue":"9","key":"10.1016\/j.bone.2020.115465_bb0140","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.035576","article-title":"Zoledronic acid prevents pagetic-like lesions and accelerated bone loss in the p62(P394L) mouse model of Paget\u2019s disease","volume":"11","author":"Daroszewska","year":"2018","journal-title":"Dis. Model. Mech."},{"issue":"14","key":"10.1016\/j.bone.2020.115465_bb0145","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1093\/hmg\/ddr172","article-title":"A point mutation in the ubiquitin associated domain of SQSMT1 is sufficient to cause a Paget\u2019s disease like disorder in mice","volume":"20","author":"Daroszewska","year":"2011","journal-title":"Hum. Mol. Genet."},{"issue":"2","key":"10.1016\/j.bone.2020.115465_bb0150","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00223-017-0265-4","article-title":"Antibody response to Paramyxoviruses in Paget\u2019s disease of bone","volume":"101","author":"Visconti","year":"2017","journal-title":"Calcif. Tissue Int."},{"issue":"12","key":"10.1016\/j.bone.2020.115465_bb0155","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1359\/jbmr.2002.17.12.2293","article-title":"The pro and con of measles virus in Paget\u2019s disease: pro","volume":"17","author":"Friedrichs","year":"2002","journal-title":"J. Bone Miner. Res."},{"issue":"12","key":"10.1016\/j.bone.2020.115465_bb0160","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1359\/jbmr.2002.17.12.2290","article-title":"The pro and con of measles virus in Paget\u2019s disease: con","volume":"17","author":"Rima","year":"2002","journal-title":"J. Bone Miner. Res."},{"issue":"11","key":"10.1016\/j.bone.2020.115465_bb0165","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/jbmr.5650061115","article-title":"Failure to detect paramyxovirus sequences in Paget\u2019s disease of bone using the polymerase chain reaction","volume":"6","author":"Ralston","year":"1991","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2020.115465_bb0170","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/jbmr.5650090103","article-title":"Absence of paramyxovirus RNA in cultures of pagetic bone cells and in pagetic bone","volume":"9","author":"Birch","year":"1994","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"10.1016\/j.bone.2020.115465_bb0175","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S8756-3282(00)00343-4","article-title":"Absence of measles virus and canine distemper virus transcripts in long-term bone marrow cultures from patients with Paget's disease of bone","volume":"27","author":"Ooi","year":"2000","journal-title":"Bone"},{"key":"10.1016\/j.bone.2020.115465_bb0180","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1210\/jc.2007-1978","article-title":"Failure to detect measles virus RNA in bone cells from patients with Paget\u2019s disease","volume":"93","author":"Matthews","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"12","key":"10.1016\/j.bone.2020.115465_bb0185","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1359\/jbmr.2000.15.12.2315","article-title":"A negative search for a paramyxoviral etiology of Paget\u2019s disease of bone: molecular, immunological, and ultrastructural studies in UK patients","volume":"15","author":"Helfrich","year":"2000","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115465_bb0190","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0169-6009(92)90923-2","article-title":"Canine distemper transcripts sequenced from pagetic bone","volume":"19","author":"Gordon","year":"1992","journal-title":"Bone Miner"},{"key":"10.1016\/j.bone.2020.115465_bb0195","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1002\/jbmr.5650111103","article-title":"Detection of measles virus nucleocapsid transcripts in circulating blood cells from patients with Paget disease","volume":"11","author":"Reddy","year":"1996","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bone.2020.115465_bb0200","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1359\/jbmr.070103","article-title":"Multicenter blinded analysis of RT-PCR detection methods for paramyxoviruses in relation to Paget\u2019s disease of bone","volume":"22","author":"Ralston","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115465_bb0205","article-title":"Bisphosphonates for Paget\u2019s disease of bone in adults","volume":"12","author":"Corral-Gudino","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"issue":"4","key":"10.1016\/j.bone.2020.115465_bb0210","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/jbmr.3657","article-title":"Diagnosis and management of Paget\u2019s disease of bone in adults: a clinical guideline","volume":"34","author":"Ralston","year":"2019","journal-title":"J. Bone Miner. Res."},{"issue":"9","key":"10.1016\/j.bone.2020.115465_bb0215","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-030689","article-title":"Zoledronate in the prevention of Paget's (ZiPP): protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent SQSTM1-mediated Paget's disease of bone","volume":"9","author":"Cronin","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.bone.2020.115465_bb0220","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.4007","article-title":"Characteristics of early Paget\u2019s disease in SQSTM1 mutation carriers: baseline analysis of the ZiPP study cohort","author":"Cronin","year":"2020","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"10.1016\/j.bone.2020.115465_bb0225","doi-asserted-by":"crossref","first-page":"e466","DOI":"10.1210\/clinem\/dgz138","article-title":"Preventive role of vitamin D supplementation for acute phase reaction after bisphosphonate infusion in Paget\u2019s disease","volume":"105","author":"Merlotti","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.bone.2020.115465_bb0230","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bone.2011.04.022","article-title":"Bisphosphonates: the first 40\u00a0years","volume":"49","author":"Russell","year":"2011","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bone.2020.115465_bb0235","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/jcb.25266","article-title":"Risks and benefits of bisphosphonate therapies","volume":"117","author":"Reyes","year":"2016","journal-title":"J. Cell. Biochem."},{"issue":"4","key":"10.1016\/j.bone.2020.115465_bb0240","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s00223-019-00578-1","article-title":"Vitamin D status in Paget disease of bone and efficacy-safety profile of cholecalciferol treatment in pagetic patients with hypovitaminosis D","volume":"105","author":"Rendina","year":"2019","journal-title":"Calcif. Tissue Int."},{"issue":"9","key":"10.1016\/j.bone.2020.115465_bb0245","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJMoa044241","article-title":"Comparison of a single infusion of zoledronic acid with risedronate for Paget\u2019s disease","volume":"353","author":"Reid","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bone.2020.115465_bb0250","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0002-9343(96)00227-6","article-title":"Biochemical and radiologic improvement in Paget\u2019s disease of bone treated with alendronate: a randomized, placebo-controlled trial","volume":"101","author":"Reid","year":"1996","journal-title":"Am. J. Med."},{"issue":"3","key":"10.1016\/j.bone.2020.115465_bb0255","first-page":"961","article-title":"Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone","volume":"81","author":"Siris","year":"1996","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"9","key":"10.1016\/j.bone.2020.115465_bb0260","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1210\/jc.2010-0597","article-title":"Characterization of and risk factors for the acute-phase response after zoledronic acid","volume":"95","author":"Reid","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.bone.2020.115465_bb0265","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos. Int."},{"issue":"1","key":"10.1016\/j.bone.2020.115465_bb0270","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2249.2005.02665.x","article-title":"The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins","volume":"139","author":"Hewitt","year":"2005","journal-title":"Clin. Exp. Immunol."},{"issue":"3","key":"10.1016\/j.bone.2020.115465_bb0275","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00223-008-9104-y","article-title":"Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro","volume":"82","author":"Idris","year":"2008","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2020.115465_bb0280","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1359\/jbmr.091009","article-title":"Fluorescent risedronate analogs reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo","volume":"25","author":"Roelofs","year":"2010","journal-title":"J. Bone Miner. Res."},{"issue":"7706","key":"10.1016\/j.bone.2020.115465_bb0285","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(71)91447-4","article-title":"Diphosphonates and Paget's disease of bone","volume":"1","author":"Smith","year":"1971","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.bone.2020.115465_bb0290","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJM197312272892601","article-title":"Influence of disodium etidronate on clinical and laboratory manifestations of Paget\u2019s disease of bone (osteitis deformans)","volume":"289","author":"Altman","year":"1973","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bone.2020.115465_bb0295","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1001\/jama.1974.03240040032027","article-title":"Treatment of Paget disease of bone (osteitis deformans). Results of a one-year study with sodium etidronate","volume":"230","author":"Khairi","year":"1974","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.bone.2020.115465_bb0300","doi-asserted-by":"crossref","first-page":"656","DOI":"10.7326\/0003-4819-87-6-656","article-title":"Sodium etidronate in the treatment of Paget\u2019s disease of bone. A study of long-term results","volume":"87","author":"Khairi","year":"1977","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.bone.2020.115465_bb0305","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/00003086-198304000-00029","article-title":"Treatment of Paget\u2019s disease of bone with ethane-1, hydroxy-1,1 diphosphonate (EHDP) at a low dosage (5\u00a0mg\/kg\/day)","volume":"174","author":"Alexandre","year":"1983","journal-title":"Clin. Orthop. Relat. Res."},{"issue":"4\u20135","key":"10.1016\/j.bone.2020.115465_bb0310","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0221-8747(81)90047-3","article-title":"Effects of ethane-1 hydroxy-1, 1-diphosphonate (5\u00a0mg\/kg\/day dose) on quantitative bone histology in Paget\u2019s disease of bone","volume":"3","author":"Alexandre","year":"1981","journal-title":"Metab Bone Dis Relat Res"},{"issue":"10","key":"10.1016\/j.bone.2020.115465_bb0315","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/art.1780231015","article-title":"Use of etidronate (EHDP) in Paget\u2019s disease of bone","volume":"23","author":"Johnston","year":"1980","journal-title":"Arthritis & Rheumatism"},{"issue":"8381","key":"10.1016\/j.bone.2020.115465_bb0320","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(84)92272-4","article-title":"Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease","volume":"1","author":"Boyce","year":"1984","journal-title":"Lancet"},{"issue":"8141","key":"10.1016\/j.bone.2020.115465_bb0325","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0140-6736(79)91551-4","article-title":"Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone","volume":"2","author":"Meunier","year":"1979","journal-title":"Lancet"},{"issue":"8444","key":"10.1016\/j.bone.2020.115465_bb0330","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/S0140-6736(85)92253-6","article-title":"Intravenous clodronate in the treatment and retreatment of Paget's disease of bone","volume":"1","author":"Yates","year":"1985","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.bone.2020.115465_bb0335","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1210\/jcem-54-4-837","article-title":"Long term effects of dichloromethylene diphosphonate in Paget\u2019s disease of bone","volume":"54","author":"Delmas","year":"1982","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.bone.2020.115465_bb0340","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/art.1780350819","article-title":"Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone. A double-blind, multiple-dosage, placebo-controlled study","volume":"35","author":"Reginster","year":"1992","journal-title":"Arthritis & Rheumatism"},{"issue":"862","key":"10.1016\/j.bone.2020.115465_bb0345","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/pgmj.73.862.496","article-title":"A double-blind, multicentre, placebo-controlled study of tiludronate in Paget\u2019s disease of bone","volume":"73","author":"Fraser","year":"1997","journal-title":"Postgrad. Med. J."},{"issue":"6","key":"10.1016\/j.bone.2020.115465_bb0350","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/art.1780380620","article-title":"Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone","volume":"38","author":"Roux","year":"1995","journal-title":"Arthritis & Rheumatism"},{"key":"10.1016\/j.bone.2020.115465_bb0355","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0140-6736(79)91318-7","article-title":"Treatment of Paget\u2019s disease with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD)","author":"Frijlink","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2020.115465_bb0360","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/bmj.295.6609.1301","article-title":"Paget\u2019s disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD)","volume":"295","author":"Harinck","year":"1987","journal-title":"Br. Med. J."},{"key":"10.1016\/j.bone.2020.115465_bb0365","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(89)90277-8","article-title":"Side effects of pamidronate","volume":"ii","author":"Gallacher","year":"1989","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.bone.2020.115465_bb0370","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/ard.45.12.1012","article-title":"Low dose intravenous 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD) for the treatment of Paget\u2019s disease of bone","volume":"45","author":"Cantrill","year":"1986","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.bone.2020.115465_bb0375","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1136\/ard.50.12.930","article-title":"Clinical experience with pamidronate in the treatment of Paget\u2019s disease of bone","volume":"50","author":"Gallacher","year":"1991","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bone.2020.115465_bb0380","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1002\/jbmr.5650051207","article-title":"Treatment of Paget\u2019s disease with intermittent low-dose infusions of disodium pamidronate (APD)","volume":"5","author":"Stone","year":"1992","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bone.2020.115465_bb0385","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.bone.2003.12.011","article-title":"A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone","volume":"34","author":"Walsh","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.bone.2020.115465_bb0390","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/jbmr.5650070112","article-title":"Effects of five daily 1\u00a0h infusions of alendronate in Paget\u2019s disease of bone","volume":"7","author":"O\u2019Doherty","year":"1992","journal-title":"J. Bone Miner. Res."},{"issue":"7","key":"10.1016\/j.bone.2020.115465_bb0395","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/jbmr.5650100714","article-title":"The effects of intravenous alendronate in Paget\u2019s disease of bone","volume":"10","author":"O\u2019Doherty","year":"1995","journal-title":"J. Bone Miner. Res."},{"issue":"10","key":"10.1016\/j.bone.2020.115465_bb0400","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1359\/jbmr.070704","article-title":"Comparison of different intravenous bisphosphonate regimens for Paget\u2019s disease of bone","volume":"22","author":"Merlotti","year":"2007","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"10.1016\/j.bone.2020.115465_bb0405","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/jbmr.237","article-title":"Comparison of intravenous and intramuscular neridronate regimens for the treatment of Paget disease of bone","volume":"26","author":"Merlotti","year":"2011","journal-title":"J. Bone Miner. Res."},{"issue":"9","key":"10.1016\/j.bone.2020.115465_bb0410","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/jbmr.438","article-title":"A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5\u00a0years","volume":"26","author":"Reid","year":"2011","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2020.115465_bb0415","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1359\/jbmr.061001","article-title":"Long-term control of bone turnover in Paget\u2019s disease with zoledronic acid and risedronate","volume":"22","author":"Hosking","year":"2007","journal-title":"J. Bone Miner. Res."},{"issue":"5 Suppl","key":"10.1016\/j.bone.2020.115465_bb0420","doi-asserted-by":"crossref","first-page":"87S","DOI":"10.1016\/S8756-3282(99)00072-1","article-title":"Ibandronate treatment in Paget's disease of bone","volume":"24","author":"Grauer","year":"1999","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bone.2020.115465_bb0425","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.bone.2004.03.023","article-title":"Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone","volume":"35","author":"Reid","year":"2004","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.bone.2020.115465_bb0430","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s00223-016-0214-7","article-title":"Long-term effects of intravenous Ibandronate in Paget\u2019s disease of bone","volume":"100","author":"Reid","year":"2017","journal-title":"Calcif. Tissue Int."},{"issue":"2","key":"10.1016\/j.bone.2020.115465_bb0435","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s002239900584","article-title":"Risedronate, a highly effective, short-term oral treatment for Paget\u2019s disease: a dose-response study","volume":"64","author":"Brown","year":"1999","journal-title":"Calcif. Tissue Int."},{"issue":"1","key":"10.1016\/j.bone.2020.115465_bb0440","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S8756-3282(97)00222-6","article-title":"Paget\u2019s disease of bone: reduction of disease activity with oral risedronate","volume":"22","author":"Hosking","year":"1998","journal-title":"Bone"},{"issue":"6","key":"10.1016\/j.bone.2020.115465_bb0445","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1359\/jbmr.1998.13.6.1032","article-title":"Risedronate in the treatment of Paget\u2019s disease of bone: an open label, multicenter study","volume":"13","author":"Siris","year":"1998","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"10.1016\/j.bone.2020.115465_bb0450","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S8756-3282(99)00271-9","article-title":"Improvement of pagetic bone lesions with risedronate treatment: a radiologic study","volume":"26","author":"Brown","year":"2000","journal-title":"Bone"},{"issue":"6","key":"10.1016\/j.bone.2020.115465_bb0455","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1359\/jbmr.1998.13.6.1032","article-title":"Risedronate in the treatment of Paget\u2019s disease of bone: an open label multicenter study","volume":"13","author":"Siris","year":"1998","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115465_bb0460","first-page":"513","article-title":"A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone","volume":"106","author":"Miller","year":"1999","journal-title":"Paget's Risedronate\/Etidronate Study Group, American Journal of Medicine"},{"issue":"5","key":"10.1016\/j.bone.2020.115465_bb0465","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s002239900255","article-title":"Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget\u2019s disease of bone","volume":"60","author":"Arden-Cordone","year":"1997","journal-title":"Calcif. Tissue Int."},{"issue":"5 Suppl","key":"10.1016\/j.bone.2020.115465_bb0470","doi-asserted-by":"crossref","first-page":"81S","DOI":"10.1016\/S8756-3282(99)00071-X","article-title":"Single infusion of zoledronate in Paget's disease of bone: a placebo-controlled, dose-ranging study","volume":"24","author":"Buckler","year":"1999","journal-title":"Bone"},{"issue":"9","key":"10.1016\/j.bone.2020.115465_bb0475","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","article-title":"Intravenous zoledronic acid in postmenopausal women with low bone mineral density","volume":"346","author":"Reid","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bone.2020.115465_bb0480","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/jbmr.3029","article-title":"Durability of response to zoledronate treatment and competing mortality in Paget\u2019s disease of bone","volume":"32","author":"Cundy","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115465_bb0485","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1359\/jbmr.090709","article-title":"Randomised trial of intensive bisphosphonate treatment versus symptomatic management in Paget\u2019s disease of bone","volume":"25","author":"Langston","year":"2010","journal-title":"J. Bone Miner. Res."},{"issue":"6","key":"10.1016\/j.bone.2020.115465_bb0490","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/jbmr.3066","article-title":"Long-term randomized trial of intensive versus symptomatic management in Paget\u2019s disease of bone: the PRISM-EZ study","volume":"32","author":"Tan","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115465_bb4915","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/jbmr.5650020103","article-title":"The effect of one alpha hydroxyvitamin D3 on the mineralisation defect in disodium etidronate treated Paget\u2019s disease - a double-blind randomised study","volume":"2","author":"Ralston","year":"1987","journal-title":"Journal of Bone and Mineral Research"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220302453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220302453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:54:25Z","timestamp":1757613265000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328220302453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":99,"alternative-id":["S8756328220302453"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2020.115465","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bisphosphonates in the management of Paget's disease","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2020.115465","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115465"}}